SE463154B - 6-fenetylaminoalkyl-furo(3,4-c)pyridinderivat,framstaellning daerav och terapeutiska kompositioner innehaallande dem - Google Patents
6-fenetylaminoalkyl-furo(3,4-c)pyridinderivat,framstaellning daerav och terapeutiska kompositioner innehaallande demInfo
- Publication number
- SE463154B SE463154B SE8504826A SE8504826A SE463154B SE 463154 B SE463154 B SE 463154B SE 8504826 A SE8504826 A SE 8504826A SE 8504826 A SE8504826 A SE 8504826A SE 463154 B SE463154 B SE 463154B
- Authority
- SE
- Sweden
- Prior art keywords
- groups
- carbon atoms
- methyl
- furo
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 7
- 230000001225 therapeutic effect Effects 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- IRIKALLDOSHXEN-UHFFFAOYSA-N 2-(7-hydroxyfuro[3,4-c]pyridin-6-yl)-3-methylbutanenitrile Chemical class OC1=C(C(C#N)C(C)C)N=CC2=COC=C21 IRIKALLDOSHXEN-UHFFFAOYSA-N 0.000 claims description 2
- BFJMHTOBRRZELQ-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-c]pyridine Chemical class N1=CC=C2C(I)=NNC2=C1 BFJMHTOBRRZELQ-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 21
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- -1 1-cyano-2-methyl-propyl Chemical group 0.000 description 22
- 238000000921 elemental analysis Methods 0.000 description 19
- 238000002844 melting Methods 0.000 description 19
- 230000008018 melting Effects 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- BZFKSWOGZQMOMO-UHFFFAOYSA-N 3-chloropropan-1-amine Chemical compound NCCCCl BZFKSWOGZQMOMO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229960001722 verapamil Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 4
- 229960003883 furosemide Drugs 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- BJDZSRHHYJRDBC-UHFFFAOYSA-N 2-(7-hydroxy-3-methyl-1,3-dihydrofuro[3,4-c]pyridin-6-yl)-3-methylbutanenitrile Chemical compound CC(C)C(C#N)C1=NC=C2C(C)OCC2=C1O BJDZSRHHYJRDBC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000010306 acid treatment Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VKPPFDPXZWFDFA-UHFFFAOYSA-N 2-chloroethanamine Chemical compound NCCCl VKPPFDPXZWFDFA-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- BIRWRIAEWIXFHT-UHFFFAOYSA-N furo[3,4-c]pyridin-7-ol Chemical class OC1=CN=CC2=COC=C12 BIRWRIAEWIXFHT-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
- 229960000620 ranitidine Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- UEJIODWLVJMTIJ-UHFFFAOYSA-N 2-(3-butyl-7-hydroxy-3-methyl-1h-furo[3,4-c]pyridin-6-yl)-3-methylbutanenitrile Chemical compound C1=NC(C(C#N)C(C)C)=C(O)C2=C1C(CCCC)(C)OC2 UEJIODWLVJMTIJ-UHFFFAOYSA-N 0.000 description 1
- APXPXBLOEUKKHC-UHFFFAOYSA-N 2-(4-chloro-3-ethyl-7-hydroxy-1,3-dihydrofuro[3,4-c]pyridin-6-yl)-3-methylbutanenitrile Chemical compound ClC1=NC(C(C#N)C(C)C)=C(O)C2=C1C(CC)OC2 APXPXBLOEUKKHC-UHFFFAOYSA-N 0.000 description 1
- FKFDZSHCYQKFJI-UHFFFAOYSA-N 2-(4-chloro-7-hydroxy-3,3-diphenyl-1h-furo[3,4-c]pyridin-6-yl)-3-methylbutanenitrile Chemical compound OC=1C(C(C#N)C(C)C)=NC(Cl)=C2C=1COC2(C=1C=CC=CC=1)C1=CC=CC=C1 FKFDZSHCYQKFJI-UHFFFAOYSA-N 0.000 description 1
- QPZFQBODLHTYNI-UHFFFAOYSA-N 2-(4-chloro-7-hydroxy-3-propyl-1,3-dihydrofuro[3,4-c]pyridin-6-yl)-3-methylbutanenitrile Chemical compound ClC1=NC(C(C#N)C(C)C)=C(O)C2=C1C(CCC)OC2 QPZFQBODLHTYNI-UHFFFAOYSA-N 0.000 description 1
- NFAFQCDWQQBDMZ-UHFFFAOYSA-N 2-(7-hydroxy-3,3-dimethyl-1h-furo[3,4-c]pyridin-6-yl)-3-methylbutanenitrile Chemical compound CC(C)C(C#N)C1=NC=C2C(C)(C)OCC2=C1O NFAFQCDWQQBDMZ-UHFFFAOYSA-N 0.000 description 1
- JFXCFBMFKLQKGN-UHFFFAOYSA-N 2-(7-hydroxy-3-methyl-1,3-dihydrofuro[3,4-c]pyridin-6-yl)acetonitrile Chemical compound C1=NC(CC#N)=C(O)C2=C1C(C)OC2 JFXCFBMFKLQKGN-UHFFFAOYSA-N 0.000 description 1
- XOTDMGSREQCMNU-UHFFFAOYSA-N 2-(7-hydroxy-3-methyl-3-phenyl-1h-furo[3,4-c]pyridin-6-yl)-3-methylbutanenitrile Chemical compound OC=1C(C(C#N)C(C)C)=NC=C2C=1COC2(C)C1=CC=CC=C1 XOTDMGSREQCMNU-UHFFFAOYSA-N 0.000 description 1
- OPECLIHJIQPJST-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)-7-hydroxy-1,3-dihydrofuro[3,4-c]pyridin-6-yl]-3-methylbutanenitrile Chemical compound O1CC2=C(O)C(C(C#N)C(C)C)=NC=C2C1C1=CC=C(F)C=C1 OPECLIHJIQPJST-UHFFFAOYSA-N 0.000 description 1
- BDFXQBPZVUMRIX-UHFFFAOYSA-N 2-[3-[4-[2-(diethylamino)ethoxy]phenyl]-7-hydroxy-3-phenyl-1h-furo[3,4-c]pyridin-6-yl]-3-methylbutanenitrile Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C1(C=2C=CC=CC=2)C(C=NC(C(C#N)C(C)C)=C2O)=C2CO1 BDFXQBPZVUMRIX-UHFFFAOYSA-N 0.000 description 1
- DWEYQIYUXMMMTN-UHFFFAOYSA-N 2-[4-chloro-3-ethenyl-7-hydroxy-3-(4-methylsulfanylphenyl)-1h-furo[3,4-c]pyridin-6-yl]-3-methylbutanenitrile Chemical compound C1=CC(SC)=CC=C1C1(C=C)C(C(Cl)=NC(C(C#N)C(C)C)=C2O)=C2CO1 DWEYQIYUXMMMTN-UHFFFAOYSA-N 0.000 description 1
- NLABPHHPAISTSI-UHFFFAOYSA-N 2-[7-hydroxy-3-(4-methoxyphenyl)-1,3-dihydrofuro[3,4-c]pyridin-6-yl]-3-methylbutanenitrile Chemical compound C1=CC(OC)=CC=C1C1C(C=NC(C(C#N)C(C)C)=C2O)=C2CO1 NLABPHHPAISTSI-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- FIPHOJZRRNESHK-UHFFFAOYSA-N 3,6-dimethyl-5-oxido-1,3-dihydrofuro[3,4-c]pyridin-5-ium-7-ol Chemical compound C1=[N+]([O-])C(C)=C(O)C2=C1C(C)OC2 FIPHOJZRRNESHK-UHFFFAOYSA-N 0.000 description 1
- HJBBKVHYQQUPQW-UHFFFAOYSA-N 3-chloro-n-[2-(3,4-dimethoxyphenyl)ethyl]-n-methylpropan-1-amine Chemical compound COC1=CC=C(CCN(C)CCCCl)C=C1OC HJBBKVHYQQUPQW-UHFFFAOYSA-N 0.000 description 1
- VUIIQPGZDMHMIV-UHFFFAOYSA-N 4-chloro-n-[2-(3,4-dimethoxyphenyl)ethyl]-n-methylbutan-1-amine Chemical compound COC1=CC=C(CCN(C)CCCCCl)C=C1OC VUIIQPGZDMHMIV-UHFFFAOYSA-N 0.000 description 1
- GMKJQTRMVFHGNL-UHFFFAOYSA-N 4-chloro-n-methyl-n-[2-(3,4,5-trimethoxyphenyl)ethyl]butan-1-amine Chemical compound COC1=CC(CCN(C)CCCCCl)=CC(OC)=C1OC GMKJQTRMVFHGNL-UHFFFAOYSA-N 0.000 description 1
- OEOOQMSPHMFXJL-UHFFFAOYSA-N 4-chlorobutan-1-amine Chemical compound NCCCCCl OEOOQMSPHMFXJL-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- XPSKXALDBYVUSX-UHFFFAOYSA-N 5-chloro-n-[2-(3,4-dimethoxyphenyl)ethyl]-n-methylpentan-1-amine Chemical compound COC1=CC=C(CCN(C)CCCCCCl)C=C1OC XPSKXALDBYVUSX-UHFFFAOYSA-N 0.000 description 1
- NQXZBUZASYJCIV-UHFFFAOYSA-N 5-chloro-n-methyl-n-[2-(3,4,5-trimethoxyphenyl)ethyl]pentan-1-amine Chemical compound COC1=CC(CCN(C)CCCCCCl)=CC(OC)=C1OC NQXZBUZASYJCIV-UHFFFAOYSA-N 0.000 description 1
- ZKSVFILTLOPGJC-UHFFFAOYSA-N 5-chloropentan-1-amine Chemical compound NCCCCCCl ZKSVFILTLOPGJC-UHFFFAOYSA-N 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- KWIIQEPCRALNSF-UHFFFAOYSA-N 6-(chloromethyl)-3-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol Chemical compound C1=NC(CCl)=C(O)C2=C1C(C)OC2 KWIIQEPCRALNSF-UHFFFAOYSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XTSJNYJEVRCAEG-UHFFFAOYSA-N n-(2-chloroethyl)-2-(3,4-dimethoxyphenyl)-n-methylethanamine Chemical compound COC1=CC=C(CCN(C)CCCl)C=C1OC XTSJNYJEVRCAEG-UHFFFAOYSA-N 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- WSDQIHATCCOMLH-UHFFFAOYSA-N phenyl n-(3,5-dichlorophenyl)carbamate Chemical compound ClC1=CC(Cl)=CC(NC(=O)OC=2C=CC=CC=2)=C1 WSDQIHATCCOMLH-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB848427218A GB8427218D0 (en) | 1984-10-27 | 1984-10-27 | Pyridine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8504826D0 SE8504826D0 (sv) | 1985-10-16 |
| SE8504826L SE8504826L (sv) | 1986-04-28 |
| SE463154B true SE463154B (sv) | 1990-10-15 |
Family
ID=10568857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8504826A SE463154B (sv) | 1984-10-27 | 1985-10-16 | 6-fenetylaminoalkyl-furo(3,4-c)pyridinderivat,framstaellning daerav och terapeutiska kompositioner innehaallande dem |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US4659719A (en, 2012) |
| JP (1) | JPS61289090A (en, 2012) |
| AR (1) | AR242212A1 (en, 2012) |
| AT (1) | AT394558B (en, 2012) |
| BE (1) | BE903438A (en, 2012) |
| CA (1) | CA1300151C (en, 2012) |
| CH (1) | CH666689A5 (en, 2012) |
| DE (1) | DE3538063A1 (en, 2012) |
| DK (1) | DK160049C (en, 2012) |
| DZ (1) | DZ850A1 (en, 2012) |
| ES (1) | ES8609330A1 (en, 2012) |
| FI (1) | FI82248C (en, 2012) |
| FR (2) | FR2572405B1 (en, 2012) |
| GB (2) | GB8427218D0 (en, 2012) |
| HK (1) | HK6289A (en, 2012) |
| IE (1) | IE59475B1 (en, 2012) |
| IT (1) | IT1190413B (en, 2012) |
| LU (1) | LU86136A1 (en, 2012) |
| MA (1) | MA20558A1 (en, 2012) |
| NL (1) | NL8502899A (en, 2012) |
| NO (1) | NO162191C (en, 2012) |
| OA (1) | OA08128A (en, 2012) |
| PT (1) | PT81365B (en, 2012) |
| SE (1) | SE463154B (en, 2012) |
| ZA (1) | ZA858004B (en, 2012) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8426738D0 (en) * | 1984-10-23 | 1984-11-28 | Scras | Pyridine derivatives |
| DE3642331A1 (de) * | 1986-12-11 | 1988-06-23 | Basf Ag | Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel |
| GB8808001D0 (en) * | 1988-04-06 | 1988-05-05 | Scras | Stereospecific preparative process for furol(3,4-c)pyridine derivatives |
| US5130252A (en) * | 1990-05-14 | 1992-07-14 | Synthetech, Inc. | Resolution of furopyridine enantiomers and synthetic precursors thereof |
| EP1207860B1 (en) | 1999-09-02 | 2007-10-24 | Nostrum Pharmaceuticals, Inc. | Controlled release pellet formulation |
| US20070095037A1 (en) * | 2007-01-18 | 2007-05-03 | Mclamb Samuel B Iii | Supplementary air filter and retainer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1551268A (en, 2012) * | 1967-12-07 | 1968-12-27 | ||
| ZA786269B (en) * | 1977-11-25 | 1979-10-31 | Scras | New pyridine derivative,its preparation and use |
| IN156817B (en, 2012) * | 1981-02-10 | 1985-11-09 | Scras | |
| IN160104B (en, 2012) * | 1983-04-05 | 1987-06-27 | Scras | |
| GB2137618B (en) * | 1983-04-05 | 1986-05-08 | Scras | Furo-(3,4-c)-pyridine derivatives |
| GB8402740D0 (en) * | 1984-02-02 | 1984-03-07 | Scras | Furo-(3 4-c)-pyridine derivatives |
| GB8422029D0 (en) * | 1984-08-31 | 1984-10-03 | Scras | 6-substituted-furo-(3 4-c)-pyridine derivatives |
-
1984
- 1984-10-27 GB GB848427218A patent/GB8427218D0/en active Pending
-
1985
- 1985-10-14 BE BE0/215724A patent/BE903438A/fr not_active IP Right Cessation
- 1985-10-15 CH CH4448/85A patent/CH666689A5/fr not_active IP Right Cessation
- 1985-10-16 SE SE8504826A patent/SE463154B/sv not_active IP Right Cessation
- 1985-10-17 ZA ZA858004A patent/ZA858004B/xx unknown
- 1985-10-20 DZ DZ850232A patent/DZ850A1/fr active
- 1985-10-21 GB GB08525939A patent/GB2166136B/en not_active Expired
- 1985-10-21 US US06/789,731 patent/US4659719A/en not_active Expired - Fee Related
- 1985-10-22 AR AR85302019A patent/AR242212A1/es active
- 1985-10-22 MA MA20782A patent/MA20558A1/fr unknown
- 1985-10-23 CA CA000493657A patent/CA1300151C/en not_active Expired - Lifetime
- 1985-10-23 FR FR8515708A patent/FR2572405B1/fr not_active Expired
- 1985-10-23 FR FR8515709A patent/FR2572285B1/fr not_active Expired
- 1985-10-23 NL NL8502899A patent/NL8502899A/nl active Search and Examination
- 1985-10-24 PT PT81365A patent/PT81365B/pt not_active IP Right Cessation
- 1985-10-24 LU LU86136A patent/LU86136A1/fr unknown
- 1985-10-25 NO NO854277A patent/NO162191C/no unknown
- 1985-10-25 DK DK490385A patent/DK160049C/da not_active IP Right Cessation
- 1985-10-25 OA OA58714A patent/OA08128A/xx unknown
- 1985-10-25 DE DE19853538063 patent/DE3538063A1/de active Granted
- 1985-10-25 IE IE264585A patent/IE59475B1/en not_active IP Right Cessation
- 1985-10-25 IT IT22612/85A patent/IT1190413B/it active
- 1985-10-25 FI FI854180A patent/FI82248C/fi not_active IP Right Cessation
- 1985-10-25 ES ES548209A patent/ES8609330A1/es not_active Expired
- 1985-10-26 JP JP60238624A patent/JPS61289090A/ja active Granted
- 1985-10-28 AT AT0310385A patent/AT394558B/de not_active IP Right Cessation
-
1989
- 1989-01-19 HK HK62/89A patent/HK6289A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4430343A (en) | Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same | |
| PL136217B1 (en) | Method of obtaining novel derivatives of 4-amino-6,7-dimetoxy-2-piprazinoquinazoline | |
| IE840826L (en) | Furo-pyridines | |
| US4826850A (en) | Quinoline base compound, process for the preparation thereof and anticancer agent containing the same as pharmacologically efficacious component | |
| US4950670A (en) | 6-phenyl-3-(piperazinyalalkyl)-2,4(1H,3H)-pyrimidinedione derivatives, their preparation and their application in therapy | |
| EP0784055A1 (en) | Pyrimidinylpyrazole derivative | |
| US4086353A (en) | Certain azolinylamino (azolidinylimino) indazoles | |
| US3845060A (en) | 1-(1-(2,3-dihydro-2-benzofuryl)-alkyl)-4-aminohexahydroisonicotinic acid amides or nitriles | |
| SE463154B (sv) | 6-fenetylaminoalkyl-furo(3,4-c)pyridinderivat,framstaellning daerav och terapeutiska kompositioner innehaallande dem | |
| US5049637A (en) | 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino-[1,2-a]azepino derivatives and 10-aza, 10-oxa and 10-thia analogues | |
| FI77864C (fi) | Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart 7-piperidino-1,2,3,5-tetrahydroimidazo /2,1-b/kinazolin-2-on. | |
| IE883136L (en) | Ó(2)-adreno receptor antagonists | |
| FI82249B (fi) | Foerfarande foer framstaellning av nya pyridinderivat. | |
| CA1173831A (en) | Process for the manufacture of novel polyazaheterocyclic compounds | |
| IE58041B1 (en) | 4-Chloro-furo-(3,4-c)-pyridine derivatives | |
| US4187373A (en) | Novel dihydrobenzanthracene derivatives | |
| EP0153746B1 (en) | 3-amino-2-hydroxypropyl derivatives of pyrimidin-4-one | |
| JPH02221274A (ja) | 新規な誘導体類 | |
| JPH01156918A (ja) | 制癌剤 | |
| Oakes | The Synthesis of Some Derivatives of Di-and Tri-Azanaphthalenes | |
| HK1001174B (en) | Imidazole derivatives, process for their preparation and their use as alpha 2-adreno-receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8504826-2 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8504826-2 Format of ref document f/p: F |